Shenzhen YHLO Biotech Co., Ltd. (SHA:688575)

Market Cap	5.57B -33.2%
Revenue (ttm)	1.79B -10.4%
Net Income	31.14M -87.3%
EPS	0.05 -88.3%
Shares Out	571.39M
PE Ratio	189.80
Forward PE	17.26
Dividend	0.02 (0.21%)
Ex-Dividend Date	Jun 27, 2025

Volume	11,474,519
Open	10.14
Previous Close	10.17
Day's Range	9.65 - 10.17
52-Week Range	9.70 - 17.00
Beta	0.31
Analysts	Strong Buy
Price Target	16.98 (+74.15%)
Earnings Date	Aug 25, 2026

About Shenzhen YHLO Biotech

Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. The company offers chemiluminescence immunoassay analyzer, diabetes solution, automated biochemical analyzer, laboratory automation, tenfly phoenix blot analyzer, VISION Pro ESR analyzer, and VISION ESR analyzer. The company was founded in 2008 and is headquartered in Shenzhen, China.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 1,664
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688575

Financial Performance

In 2025, Shenzhen YHLO Biotech's revenue was 1.81 billion, a decrease of -9.99% compared to the previous year's 2.01 billion. Earnings were 23.34 million, a decrease of -92.26%.